Lots up, Madman, but I am deeply prejudiced.
Galliprant saved our dog's life but we got a shock when CEO St. Peter claimed PETX "owned" the osteoarthritis indication.
I have since found there are a host of biotechs attempting to treat numerous diseases and problems by antagonizing [shutting down the production of harmful proteins] by the same EP4 receptor.
The statement about a complicated receptor was akin to calling nuclear war a dustup.
Our supplier of Galliprant by mail order that requires a prescription rates Galliprant inferior to even a generic.
Then I found a claim numerous numerous biotechs [including Eli Lilly that leased the drug to PETX?] were attempting approval of a similar drug to Galliprant antagonizing the human EP4 receptor.
My wife is badly crippled by the same arthritis as the dog and only long testing will tell if it works as well [or at all] for humans.
Whatever the case, PETX has had a string of successes that should soon make the financials great reading.
JMO.
Best, Terry
News 
Market Data 
Discover 
